Innovations and recent trends in the treatment of ADHD

Vishal Madaan, Shannon Kinnan, Joan Daughton, Christopher J. Kratochvil

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

Original languageEnglish (US)
Pages (from-to)1375-1385
Number of pages11
JournalExpert Review of Neurotherapeutics
Issue number9
StatePublished - Sep 2006


  • Atomoxetine
  • Attention-deficit hyperactivity disorder
  • Modafinil
  • NRP-104
  • Pharmacotherapy
  • Stimulants
  • Transdermal

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Innovations and recent trends in the treatment of ADHD'. Together they form a unique fingerprint.

Cite this